Takeda Pharmaceutical Co Ltd
TKDA
Company Profile
Business description
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Contact
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo103-8668
JPNT: +81 332782306
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
47,455
Stocks News & Analysis
stocks
ASX healthcare leader sees further cuts to fair value
Fiercer competition expected to squeeze margins.
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,942.80 | 10.30 | 0.12% |
| CAC 40 | 8,057.36 | 142.00 | 1.79% |
| DAX 40 | 23,968.63 | 559.26 | 2.39% |
| Dow JONES (US) | 47,857.06 | 116.26 | 0.24% |
| FTSE 100 | 10,412.24 | 162.72 | 1.59% |
| HKSE | 25,959.90 | 551.44 | 2.17% |
| NASDAQ | 22,697.10 | 1.16 | 0.01% |
| Nikkei 225 | 54,248.39 | 1,519.67 | 2.88% |
| NZX 50 Index | 13,213.39 | 114.56 | 0.87% |
| S&P 500 | 6,807.19 | 11.20 | 0.16% |
| S&P/ASX 200 | 8,711.40 | 7.00 | 0.08% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |